Although microsatellite-stable (MSS) CRC typically shows a low response rate to PD-1/PD-L1 inhibitors, interventions targeting the bacterial microbiota have been shown to improve treatment efficacy (62). The gene discussed is PDCD1; the disease is colorectal carcinoma.